SEC Info - AC Immune SA - ‘6-K’ for 11/13/19

SEC Info℠

Home

Help

Please Sign In

AC Immune SA – ‘6-K’ for 11/13/19

On: Wednesday, 11/13/19, at 6:34am ET · For: 11/13/19 · Accession #: 950103-19-15378 · File #: 1-37891

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/13/19  AC Immune SA                      6-K        11/13/19    5:827K                                   Davis Polk & … LLP 01/FA

Current Report by a Foreign Issuer — Form 6-K — Rule 13a-16 / 15d-16
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current Report by a Foreign Issuer                  HTML     10K 
 2: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML    173K 
 3: EX-99.1     Miscellaneous Exhibit                               HTML    139K 
 4: EX-99.2     Miscellaneous Exhibit                               HTML     62K 
 5: EX-99.3     Miscellaneous Exhibit                               HTML     59K

‘6-K’ — Current Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2019

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

	EPFL Innovation Park Building B 1015 Lausanne, Switzerland
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☒

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AC IMMUNE SA


	By:	/s/ *Andrea Pfeifer*
		Name: Andrea Pfeifer
		Title: Chief Executive Officer

	By:	/s/ *Joerg Hornstein*
		Name: Joerg Hornstein
		Title: Chief Financial Officer

Date: November 13, 2019

EXHIBIT INDEX

Exhibit Number	Description
3.1	Articles of Association dated July 8, 2019
99.1	Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Nine Months Ended September 30, 2019
99.2	Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3	Press Release dated November 13, 2019

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	11/13/19	None on these Dates
	9/30/19
	7/8/19
		List all Filings

↑Top

Filing Submission 0000950103-19-015378 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)